{"id":"NCT02250807","sponsor":"Janssen R&D Ireland","briefTitle":"Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection","officialTitle":"A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive or -Experienced Subjects With Chronic Genotype 4 Hepatitis C Virus Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01","primaryCompletion":"2015-12","completion":"2015-12","firstPosted":"2014-09-26","resultsPosted":"2016-11-17","lastUpdate":"2016-11-17"},"enrollment":40,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C","Genotype 4 Chronic Hepatitis C"],"interventions":[{"type":"DRUG","name":"Simeprevir","otherNames":["TMC435"]},{"type":"DRUG","name":"Sofosbuvir","otherNames":[]}],"arms":[{"label":"Simeprevir and Sofosbuvir","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to show superiority of simeprevir (SMV) in combination with sofosbuvir for 12 weeks versus a historical control. Historical control will be a composite of the observed historical sustained virological response at Week 12 (SVR12) rates of SMV in combination with (pegylated) interferon (PegIFN)/ribavirin (RBV) of the subpopulations in study HPC3011 (NCT01567735) and will depend on the percentage of treatment-naive, prior relapser, prior non-responder, interferon (IFN)-intolerant and other subjects enrolled in this study.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Treatment (EOT) (SVR12)","timeFrame":"12 weeks after EOT","effectByArm":[{"arm":"SMV+SOF 12 Weeks","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":6,"countries":["Spain"]},"refs":{"pmids":["27896822"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":["Headache","Asthenia","Catarrh","Erythema","Rash"]}}